Variant · Snv
EGFR R831H
CI-VAR-00003911Explore in graph →NP_005219.2:p.Arg831HisNM_005228.4:c.2492G>AClinVar 560007 CIViC 1017 rs150036236
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20966921
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma3 | ||||||||
| EGFR R831H | Gefitinib | Predictive | B | Supports Sensitivity Response | — | submitted | EID2618EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. Ligand binding causes receptor homo- or hetero-dimerization, leading to acti… (full text at CIViC) PMID 20966921 · Pao et al., 2010 · Open in CIViC | civic |
| EGFR R831H | Gefitinib | Predictive | B | Supports Sensitivity Response | — | submitted | EID2619EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. PMID 15870435 · Cappuzzo et al., 2005 · Open in CIViC | civic |
| EGFR R831H | ||||||||
ClinVar
Clinical significance (1)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
- Source
- NCBI ClinVar (variant_summary)
- Dataset
- ClinVar variant_summary
- Version
- 2026-09-06
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- database
- License
- Public domain (US Government work, NCBI/NLM); acknowledgment requested
- Run
- ING-CLINVAR-20260908-000001
| Variation | Clinical significance | Review status | Stars | Conditions | Origin | Submitters | Last evaluated | Source |
|---|---|---|---|---|---|---|---|---|
| 560007 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications | 1 | Squamous cell lung carcinoma; Lung adenocarcinoma; EGFR-related lung cancer; Hereditary cancer-predisposing syndrome | germline | 6 | Mar 30, 2025 | clinvar |